Exocrine Pancreatic Insufficiency Market Share, Trends, Growth, Analysis And Forecast 2024-2033

The new report published by The Business Research Company, titled ""Exocrine Pancreatic Insufficiency Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.41 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%.

Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13107&type=smp

Increasing Prevalence Of Chronic Diseases Boosts Growth Prospects For The Exocrine Pancreatic Insufficiency (EPI) Market
The rise in chronic diseases is expected to propel the growth of the exocrine pancreatic insufficiency market going forward. Chronic diseases are long-term medical conditions that persist over an extended period, typically three months or more. The prolonged presence of the underlying disease can also increase the likelihood of developing secondary complications like exocrine pancreatic insufficiency, which fuels the better management of chronic conditions through medical interventions and therapies and can lead to longer life spans for individuals with these conditions. For instance, in January 2023, according to a report published by the National Library of Medicine, a US-based agency, the number of individuals aged 50 years and older having one or more chronic illnesses and is projected to rise by 99.5%, reaching 142.66 million by 2050, up from 71.522 million in 2020 in the United States. Therefore, the rise in chronic diseases will drive the growth of the exocrine pancreatic insufficiency market.

Enhancing Patient-Centric Approaches In The Exocrine Pancreatic Insufficiency Market
Major companies operating in the exocrine pancreatic insufficiency market are focusing on creating patient advocacy groups to support patient-centric product development. Patient advocacy groups in exocrine pancreatic insufficiency (EPI) are organizations dedicated to supporting and advocating for individuals affected by exocrine pancreatic and empowering individuals to learn about their condition and treatment options. For instance, in November 2021, Aimmune Therapeutics, Inc., a US-based biopharmaceutical company specializing in exocrine pancreatic insufficiency (EPI) and chronic pancreatitis treatment, partnered with Mission: Cure, a US-based nonprofit organization dedicated to EPI treatment, to introduce a new online patient community on the HealthUnlocked network. This platform offers crucial support and information to patients with pancreatitis, including exocrine pancreatic insufficiency (EPI). The district serves as a space for patients to connect, share their experiences, and receive support for managing chronic pancreatitis and related conditions.

The exocrine pancreatic insufficiency market covered in this report is segmented -

1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13107&type=discount

Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan plc, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma Plc, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc, Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics

Contents of the report:
1. Executive Summary
2. Exocrine Pancreatic Insufficiency Market Report Structure
3. Exocrine Pancreatic Insufficiency Market Trends And Strategies
4. Exocrine Pancreatic Insufficiency Market - Macro Economic Scenario
5. Exocrine Pancreatic Insufficiency Market Size And Growth
…..
27. Exocrine Pancreatic Insufficiency Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.